The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA 92121-2133, USA
Tel:
Work +1 858 677 1400
Fax:
Fax +1 858 677 1401
Web:
www.dlapiper.com

Larry Nishnick

Tel:
Work +1 858 677 1414
Email:
Web:
www.dlapiper.com/en/us/people/n/nishnick-larry-w/
DLA Piper LLP (US)

Work Department

Corporate; Media, Sport and Entertainment; Technology; Life Sciences

Position

Partner

Career

Larry Nishnick advises both private emerging growth companies and established, public company clients throughout a broad range of industries, including technology, software, life sciences and healthcare, sports, media, entertainment, consumer products and retail, consumer finance, cleantech and the internet of things. Larry also advises private equity, venture capitalists and angel investors in connection with their investments.

Larry advises clients from the initial formation and early-stage fundraisings through later-stage venture capital and private equity financings to IPOs and follow-on offerings, PIPEs and debt financings. Larry has extensive experience in mergers and acquisitions, joint ventures, partnerships, collaborations and other strategic transactions. Larry's practice also includes SEC disclosure and reporting requirements, including 1933 Act and 1934 Act disclosure and the reporting requirements of NYSE, NASDAQ and AMEX.

 

Education

J.D., University of San Diego School of Law; B.A., Washington & Jefferson College


United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Co-heads of DLA Piper LLP (US)'s practice, San Diego-based Lisa Haile and Matthew Holian in Boston, specialize in patentability and licensing strategies, and product liability and mass tort, respectively. Recent highlights include obtaining issuance of multiple patents for Aegis Therapeutics’ key product areas and assisting Pfizer and Bristol-Myers Squibb (BMS) with multidistrict and state court litigation concerning alleged defects of the clients’ blockbuster anticoagulant medication Eliquis. New York-based litigator Loren Brown has been acting for Medtronic and Covidien in product liability litigation related to complications allegedly caused by some of Covidien’s implantable hernia mesh products. San Diego’s Larry Nishnick and Austin’s Aaron Fountain are names to note for corporate investment and patent litigation respectively.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to